Computed tomography during hepatic arteriography pattern may predict hepatocellular carcinoma recurrence following transarterial chemoembolization

Katayama, Kazuhiro; Ohkawa, Kazuyoshi; Imanaka, Kazuho; Sakakibara, Mitsuru; Miyazaki, Masao; Kimura, Haruki; Ishihara, Akio; Matsunaga, Takashi; Murata, Masayuki; Nakazawa, Takahiro; Nakanishi, Katsuyuki

doi:10.1111/hepr.12337

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Katayama et al . reported that CMN type showed significantly higher recurrence after TACE 40 . In our study, CMN type showed poor prognosis in the univariate analysis but not in the multivariate analysis.…”

Section: Discussioncontrasting

confidence: 60%

Transarterial‐ chemoembolization remains an effective therapy for intermediate‐stage hepatocellular carcinoma with preserved liver function

Saito

Tanaka

Nishiohuku

et al. 2020

Hepatology Research

View full text Add to dashboard Cite

To evaluate outcomes as well as prognostic factors of transarterial chemoembolization (TACE) in intermediate stage hepatocellular carcinoma (HCC) with preserved liver function to determine positioning of TACE. Methods: Of 158 treatment naïve patients with intermediate stage HCC who received initial TACE from February 2007 to January 2016, 113 patients met the following inclusion criteria: no combined therapy within 4 weeks after initial TACE, and Child-Pugh score under 7. Response rate and overall survival were evaluated. The prognostic factors were investigated in univariate and multivariate analyses using Cox proportional hazards models. The deterioration of liver function after repeated TACE was also evaluated. Results: The response rate was 92.7% (complete response, 63.3%; partial response, 29.4%). The median survival time was 45.2 months. Survival rates at 1, 2, and 3 years were 90.4%, 77.0%, and 60.8% respectively. Age ≥ 75 years (P=0.022), serum α fetoprotein level ≥ 200 ng/mL (P=.010), tumor number ≥ 11 (P=0.008), and heterogeneous enhancement on dynamic computed tomography (P=0.024) were poor prognostic factors. The deterioration rate of Child-Pugh score and albuminbilirubin grade was 18.5% and 12.3%, respectively, after the first TACE, 15.6% and 5.1%, respectively, after the second TACE, and 14.5% and 11.1%, respectively, after the third TACE. Conclusion: Superselective TACE can achieve high tumor response rates with prolonged overall survival for patients with intermediate stage HCC with preserved liver function. Age, serum α fetoprotein level, tumor number ≥ 11, and heterogeneous enhancement on dynamic computed tomography indicated significantly poor prognosis.

show abstract

Section: Discussioncontrasting

confidence: 60%

Transarterial‐ chemoembolization remains an effective therapy for intermediate‐stage hepatocellular carcinoma with preserved liver function

Saito

Tanaka

Nishiohuku

et al. 2020

Hepatology Research

View full text Add to dashboard Cite

show abstract

Treatment strategy for and malignant potential of hepatocellular carcinoma within the Milan criteria

Katayama

2021

Acta hepatologica Japonica

View full text Add to dashboard Cite

Computed tomography during hepatic arteriography pattern may predict hepatocellular carcinoma recurrence following transarterial chemoembolization

Abstract: Patients with pattern 2 hepatocellular carcinoma and/or four or more lesions may have a relatively high recurrence rate after transarterial chemoembolization.

Cited by 2 publications

References 38 publications

Transarterial‐ chemoembolization remains an effective therapy for intermediate‐stage hepatocellular carcinoma with preserved liver function

Transarterial‐ chemoembolization remains an effective therapy for intermediate‐stage hepatocellular carcinoma with preserved liver function

Treatment strategy for and malignant potential of hepatocellular carcinoma within the Milan criteria

Contact Info

Product

Resources

About